Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $45,188.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,077,172. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Friday, July 12th, Michael Chi sold 9,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total transaction of $204,886.00.
• On Monday, June 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.07, for a total transaction of $381,877.21.
• On Thursday, June 20th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.50, for a total transaction of $183,750.00.

Hims & Hers Health Stock Down 5.0 %

Shares of HIMS opened at $17.58 on Monday. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -1,758.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The stock’s 50-day moving average price is $21.37 and its 200-day moving average price is $15.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.05) EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Certuity LLC acquired a new position in Hims & Hers Health in the 4th quarter worth about $109,000. Van ECK Associates Corp purchased a new position in Hims & Hers Health during the second quarter worth approximately $111,000. Belpointe Asset Management LLC grew its holdings in Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Finally, Custom Index Systems LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $132,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on HIMS shares. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Canaccord Genuity Group began coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Finally, Jefferies Financial Group lifted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.07.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.